text:
Contact Us
Diana BartlettAssistant Vice President,
Corporate Partnerships
Phone: (909) 607-9864
Email: diana_bartlett[at symbol]kgi.edu
Previous Year's Presentations
Global Regulatory Landscape and U.S. Regulatory Strategy for Lung Cancer, Hypercalcemia of Malignancy and Graft Versus Host Disease
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes to dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company. As Amgen continues to build a pipeline of therapeutic medicine with breakaway potential, its current products provide improved therapies to millions of patients around the world.
The Amgen Regulatory TMP developed regulatory landscapes for hypercalcemia of malignancy and lung cancer during the 1st semester. During the second semester, the team focused on a similar document for Graft Versus Host Disease (GVHD). Finally, the team developed a regulatory strategy for a hypothetical GVHD product seeking approval in the US marketplace. These landscapes and this strategy were presented to the senior staff of Amgen. The team will present the 2nd semester effort focused on GVHD.
To construct an FDA regulated landscape for therapies directed at GVHD, the team first characterized the disease demographics and pathologies. This work was then expanded to include an examination of the literature for previously approved therapies, clinical studies and investigational treatments for this disease. Ultimately, the team located essential public information and compiled a series of milestone reports with key observations and insights which might help guide Amgen as it navigates the regulatory barriers for GVDH disease. The Amgen TMP provided the student team with an excellent experience in the regulatory challenges associated hypercalcemia of malignancy, lung cancer and GVHD. Ultimately, the TMP team provided Amgen with detailed supporting information for these diseases as well as some discussion of the potential regulatory approaches to pursue investigational drugs in these therapeutic areas.
Benchmarking Study to Evaluate Best Practices in Supply Chain Management
Amgen, Inc., a world class biopharmaceutical company, discovers, develops, manufactures and delivers therapeutic products for the disease areas of oncology, hematology, inflammation, bone health, nephrology and cardiovascular diseases. Since its founding in 1980, Amgen has grown rapidly to attain a market capitalization of $91 billion with a world-wide presence in over 50 countries. Amgen currently produces 12 products for 20 different disease indications while pursuing numerous additional drugs through Amgen R&D. Amgen is headquartered in Thousand Oaks, California and employs 20,000 staff worldwide.
As Amgen's network evolves and grows to supply more countries with more products, their supply chain will face increasing challenges in planning, sourcing, and delivery. As a result of this growth, Amgen has sought to evaluate optimal supply chain models to ensure time to market, outstanding patient supply and efficient delivery of its products across world markets.
The Amgen Supply Chain TMP was asked to benchmark supply chain best practices across a number of selected industries. Model companies were chosen, by brainstorming with Amgen liaisons, from industries with high value products, stringent regulations, or highly efficient supply chain behaviors. The team gathered information about supply chain management and supply chain strategies for these prominent targeted companies in the pharmaceutical, biotechnology, diagnostic, consumer technology and e-commerce industries. From this research, the Amgen Supply Chain TMP identified best practices and common trends within and across these industries. After analyzing these industrial trends, the KGI team pursued two focus areas in the spring semester: global trade management and inventory management. Ultimately, the team performed an in-depth qualitative analysis of supply chain opportunities before making recommendations to Amgen regarding their use of new tools in global trade management and inventory management.
Optimization of the Capital Asset Procurement Process
BioMarin Pharmaceutical, Inc. began developing and commercializing therapies for rare genetic diseases in 1997. Their strategy to develop first-to-market therapies with an orphan disease status has been remarkably successful resulting in a product portfolio with five approved products and multiple pre-clinical and clinical candidates. Strategically, BioMarin intends to continue to focus on areas of high unmet medical need and to leverage their expertise to improve health outcomes for patients.
BioMarin's five-year trend reveals an average revenue growth of 14% each year. This level of growth has encouraged BioMarin to re-examine strategic aspects of the operations organization to more efficiently support the growing list of products. As BioMarin pursues major milestones in 2014 including the launch of a new drug, Vimizin, it is critical their processes withstand the influx of new projects as well as the increasing workload. BioMarin has undertaken the task of defining their 'Invest-to-Divest End to End Business Process' with an end goal of alignment, efficient decision-making, and communication. The BioMarin TMP team was tasked to analyze current business processes and assist in developing the 'Deliver Capital Assets' sub-processes.
Risks, resources, cost, and time-to-implement have been identified as key performance metrics to consider when devising recommendations for improved capital procurement efficiency. By analyzing primary and secondary literature and conducting interviews with key stakeholders at BioMarin and industry leaders, the team has exposed areas of inefficiencies in the process and identified factors that differentiate BioMarin from leaders in the industry. Upon completion of the project, the team delivered five specific recommendations outlining changes that might have the greatest potential to benefit BioMarin. The team provided detailed justification for implementing these recommendations and has assigned a process owner within BioMarin to facilitate the implementation of these solutions.
Evaluating and Optimizing the Perfusion Process for a CMO Universal Platform
Boehringer Ingelheim (BI), headquartered in Germany, is one of the world's leading contract manufacturing organizations (CMO) and one of the largest privately-held life science companies. BI has an established position in the biologics market having brought over 20 products successfully to the market for companies such as Amgen, Bayer, Genentech, and Pfizer. Overall, BI provides a comprehensive CMO platform with diverse capabilities from cell line development to product fill and finish, including the capacity to scale from clinical to commercial production. BI's mission is to add value through innovation includes investigating the potential benefits of the perfusion process.
The perfusion process offers an excellent solution for the manufacturing of unstable proteins. Perfusion allows proteins to be quickly removed from a cell culture bioreactor and stored under stable conditions for further processing rather than remaining in a potentially damaging cell culture environment. Furthermore, perfusion offers Boehringer Ingelheim the opportunity to reduce costs by using smaller scale bioreactors than the traditional setup for batch or fed batch cell cultivation. The goal of the BI TMP was: to grow and achieve a very high cell density on various cell lines; compare the retention analysis for the BI media versus commercial media; and, compare the density and product concentration of the fed-batch and perfusion process modes.
Successful perfusion experimental runs, for baseline data analysis, were conducted during the fall semester using commercialized media on various CHO (Chinese Hamster Ovary) cells. During the spring semester, the team ran various experiments utilizing adapted cell lines and collected valuable information which provided insights into the advantages of the BI proprietary media over the commercial media. By demonstrating, via the perfusion process, the ability of multiple cell lines to reach and maintain a high density in the BI media, the BI Perfusion Process TMP validated important aspects of the perfusion process. Ultimately, this information provided BI with critical data which supported the potential of a universal mammalian cell perfusion platform for the manufacturing of pharmaceutical products.
Streamlining the Quality Control Method Transfer Process
Boehringer Ingelheim (BI), headquartered in Ingelheim, Germany, is a family-owned global corporation founded in 1885 which is focused on Human Pharmaceuticals and Animal Health. The BI site in Fremont, CA is a division of the Global Biopharmaceutical Network. BI Fremont has state-of-the-art process development and manufacturing equipment with the capacity to annually produce over 200,000 liters (L) of cell culture product. BI Fremont currently supports both GMP clinical and commercial production, and has a global track record of over 140 biologic projects including 22 commercial products.
Due to the commercial and clinical production capability, capacity, and flexibility of the BI facility, many companies contract with BI as a Contract Manufacturing Organization (CMO). This contract business generates significant revenue to the company. Concomitant to transferring the manufacturing process to BI, these companies must also transfer analytical methods which ensure the product's efficacy, strength, purity, integrity, quality, and safety. These methods allow on-site/real-time testing for in-process sampling, as well as release and stability testing. Unfortunately, method transfers can be tedious and may take up to 60-90 days to complete. Additionally, because there are approximately 10 method transfers per project, project transfer timelines can take as long as 8-9 months. Lastly, because there may be as many as 3-5 concurrent projects, the organization may be transferring 30-50 methods at a time.
The BI Quality Control TMP was tasked with analyzing the current method transfer processes and implementing solutions to streamline the process and reduce method transfer times. The BI TMP team approached this project using the DMAIC (Define, Measure, Analyze, Improve, Control) methodology to construct a current-state process map, identify bottlenecks, eliminate waste in the system, and develop a future-state process map. Additionally, the team interviewed clients to gain input from the customer and conducted industry research to determine how many methods might be waived. This research and analysis enabled the team to create and implement solutions to streamline the method transfer process. In conclusion, the BI TMP Team made recommendations which should enable BI to expedite method transfers. It is hoped that these recommendations might allow Boehringer Ingelheim to reduce the cost and time required for method transfers - and, ultimately allow BI to tackle more projects and generate more revenue.
Brace Pharmaceuticals
Evaluation and Recommendation of Investment Opportunities in Rare Diseases
Brace Pharmaceuticals, Inc., is an investment company created by EMS S/A, the largest pharmaceutical company in Brazil. Brace Pharmaceuticals is looking for partners interested in co-developing pharmaceutical products that complement its corporate and product development strategy. These opportunities include innovative, life-changing therapies for diseases with high unmet medical need, including orphan diseases.
Brace Pharmaceuticals intends to diversify its project portfolio by investing 80% of its funds in late-stage clinical phase projects and 20% in earlier phase projects. Brace's initial investments have been completed and evaluation of additional feasible projects is ongoing. The Brace TMP's main objective was to identify a short-list of projects that complement Brace's investment strategy in the area of rare diseases.
The team focused its initial efforts on evaluating potential candidates that have been granted orphan designations, orphan product approvals and/or awarded FDA grants to support clinical studies for rare diseases. These viable candidates were then analyzed based on scientific and medical rationale, regulatory considerations, intellectual property rights, and commercial potential. Future efforts will focus on identification and evaluation of candidates which have been approved in other markets.
City of Hope Beckman Research Institute
Development and Commercialization Strategy for Novel Epigenetic Cancer Therapy
City of Hope is a renowned non-profit organization focused on world-class research and treatment for cancers and other life-threatening diseases. The Beckman Research Institute (BRI) is one of six key strategic research programs at City of Hope, responsible for expanding the world's biological understanding of diseases such as cancer, HIV/AIDS and diabetes. The BRI encompasses over 60 years of expertise in scientific research, where investigators are committed to identifying opportunities at the cellular and molecular level to predict, prevent, diagnose, treat and cure such serious diseases.
The BRI is interested in cancer related epigenetics, particularly in gene-regulatory proteins involved in cancer expression. Epigenetic regulators alter gene expression without changing actual DNA sequences. A class of proteins important for epigenetic regulation, histone methyltransferases (HMTs), plays multiple important roles in certain cancers. The BRI has recently developed a novel class of chemical entities that target a specific HMT for potential cancer treatment. This class of compounds targets a promising new therapeutic area that may have significant application in a number of cancer indications.
The City of Hope Epigenetics TMP team was tasked with creating a product development and commercialization plan for a potential epigenetic cancer therapy, based on a novel HMT inhibitor developed at the Beckman Research Institute. Throughout the project, the team investigated standards of care in a number of cancer indications, conducted detailed interviews with key opinion leaders in the field, and performed market and competitive analyses to evaluate the commercial potential of a new epigenetic cancer therapy. This effort resulted in the final deliverable which included a strategic recommendation outlining the critical steps needed to maximize the potential for commercial, clinical, and regulatory success of this new therapy.
City of Hope Beckman Research Institute
Developing a Business Plan for HIV Stem Cell Therapies
City of Hope is a leading research and treatment center for cancer and other life-threatening diseases. It includes the Comprehensive Cancer Center, the Beckman Research Institute, and the Irell and Manella Graduate School of Biological Sciences. The City of Hope celebrated its 100th anniversary in 2013 and is located in Duarte, California. Research at the City of Hope focuses on cancer biology, diabetes, immunology, and virology.
The Beckman Research Institute at City of Hope has developed a novel gene-modified stem cell therapy to treat HIV. To support this therapy, the City of Hope has just completed a human clinical trial which demonstrated the safety of the autologous stem cell product. To help the Beckman Research Institute commercialize its technologies, the City of Hope engaged KGI to assess the feasibility of commercialization through creation of a spin-off company.
The City of Hope HIV Therapies TMP team was charged with creating a business plan and commercialization strategy for this stem cell therapy. To accomplish this goal, the team: conducted a competitive analysis of current HIV therapies; performed primary and secondary market research regarding the RNA-based science of this therapeutic technology; and studied the unique challenges of commercializing a gene-therapy product. After reading key scientific articles and speaking to subject matter experts in venture capital, regenerative medicine, regulatory approval, technology transfer, and biotech operations, the team developed a comprehensive business plan. The plan highlights the market potential for HIV gene therapeutics; identifies critical marketing risk factors; and recommends an IP, marketing, operations and development strategy for the new firm. The business plan also includes detailed financial projections and identifies a series of funding milestones for equity investors to fund its operations.
Edwards Lifesciences
Design, Implementation, and Testing of a New Biomedical Engineering Test Bench
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Founded in 1958, Edwards has grown into a global company with a presence in approximately 100 countries and more than 7,800 employees around the world. Edwards focuses on medical technologies that address large and growing patient populations in which there are significant unmet clinical needs, such as structural heart disease and critical care monitoring.
Edward's hemodynamic monitoring instruments measure cardiovascular parameters that are derived from sensor data. Typically, sensors are attached to, or integrated within catheters, which are inserted into blood vessels. Catheter associated sensors then generate signals that allow healthcare personal to make conclusions about patients' health. Sophisticated algorithms within Edward's patient monitoring software interpret these cardiovascular signals so that advanced health information can be displayed. Unfortunately, the only way Edwards can test these algorithms and their patient monitoring devices is through the use of animal studies and recorded patient data from a limited patient population. Further, many of Edward's available test benches are limited in function and cannot be used for complex R&D investigations. Yet test bench analysis is essential in understanding the various cardiovascular signals found in the field.
The core goal of the Edwards TMP was to facilitate software design, implementation, and testing of a new biomedical engineering test bench which would permit the testing and validation of Edward's products. The project focused on four interrelated subprojects: physiological modeling, embedded systems development, and physical experimentation. The key objective of the physiological modeling group is to further develop Edward's cardiovascular modeling tools making them more robust and easier to use. The key objective of the embedded systems development and the physical experimentation subgroup is to create a reliable and fully developed test bench which accurately simulates cardiovascular signals and expands Edward's cardiovascular research capabilities. In conclusion of the Edwards TMP, the team developed a signal test bench which is expected to enhance Edwards research capabilities. This test bench utilizes PythonTM tools for aortic pressure signal generation and modeling, and a physical test bench with protocols for performing frequency response experiments with Edwards products.
Eli Lilly & Company
Chorus Value Proposition Identification and Communication
Chorus is an autonomous group within Eli Lilly and Company that functions to determine the proof-of-concept of new clinical development molecules (assets) quickly, efficiently, and at low cost. Chorus was initially developed by Lilly as part of a fast-to-fail approach for secondary internal assets. It was hoped that this approach would reduce the cost of failed molecules yet accelerate the development of molecules with a successful proof-of-concept outcome by rapidly delivering them to the internal Lilly pipeline. Since its inception Chorus additionally developed assets from sources outside of Lilly-specifically assets funded directly or indirectly by Lilly's Capital Funds Strategy. These assets, selected for development by Chorus, were from therapeutic areas that matched those of Lilly's portfolio.
During the transition from developing "internal only" Lilly assets to developing assets from outside sources, some confusion has developed about the role of Chorus within Lilly. Simultaneously, the value of Chorus to external customers and Lilly's internal research engine has changed. Chorus has no desire to become a solely contract research organization which develops assets on a fee for service basis. Consequently, Chorus needed to identify their core capabilities and clarify their value to both their internal Lilly R&D as well as their external customers. Finally, Chorus wished to identify areas of research which were of particular value to their customers.
To support Chorus' goals, the KGI team was tasked with interviewing and surveying Chorus team members to identify the internal perceptions of their key capabilities as well as the areas they need to improve. Additionally, the team interviewed current and potential customers to crystallize their view of Chorus' strengths and weaknesses, the value of their capabilities, and to compare the internal and external customer perceptions of Chorus' capabilities. After generating a complete list of capabilities, current and potential customers were segmented based on their motivation and their needs in seeking development activities from Chorus. Lastly, the team analyzed the competitive landscape, and made recommendations for improving the communication of Chorus' value to current and potential customers.
Eli Lilly & Company
Social Media Data Mining for Patient Insight into Pharmaceutical Product Design
Eli Lilly and Company is a global, research-based pharmaceutical firm headquartered in Indianapolis, Indiana. Founded more than 135 years ago, Lilly is at the forefront of pharmaceutical research and development in both small molecules and biologics. Lilly's portfolio contains products that meet medical needs in the therapeutic areas of oncology, cardiovascular disease, diabetes, musculoskeletal disease, neuroscience, critical care and men's health. Eli Lilly's products are sold in more than 125 countries and include the blockbuster drugs Evista®, Cymbalta®, Humalog®, Gemzar® and Cialis®.
Eli Lilly believes that social media could represent a viable channel to understand patients' needs better. People regularly discuss their health and treatment options online. These conversations on social media websites may offer different points of view from traditional venues and may provide unique insight to drive pharmaceutical product design and innovation.
The Eli Lilly TMP team was asked to conduct a feasibility study to determine if valuable patient insight could be obtained from Twitter for the therapeutic areas of rheumatoid arthritis and Alzheimer's disease. To accomplish this goal, the TMP team worked with a third-party vendor to procure Twitter datasets. The team then analyzed these datasets utilizing Big Data analytic approaches to provide Lilly with recommendations on ways to apply these insights in product design. Additionally, the team provided Lilly with an algorithm which can be applied to other therapeutic areas of interest. In conclusion, the Lilly Data Mining TMP team provided an analysis of the potential options and limitations of leveraging the social media space. Furthermore, the TMP team clarified the constraints of leveraging social media in a highly regulated environment. As a follow-up to the Lilly Data Mining TMP research, the team expects to present its findings at a national conference in June.
Eli Lilly & Company
Regulatory Competitive Intelligence: Opportunities and Advantages Associated with Regulatory Interactions with the FDA
Eli Lilly & Co. is an Indianapolis- based company founded in 1876 with a vision to make medicines that help people live longer, healthier, and more active lives. The company continues to be committed to making a significant contribution to humanity by improving global health in the 21st century. Lilly has developed a diverse portfolio in several therapeutic areas, i.e. bone muscle joint, cardiovascular, diabetes, men's health, neuroscience and oncology. Lilly was the first company to mass-produce penicillin, the Salk polio vaccine and insulin. Lilly has locations in 18 countries and their products are sold in 125 countries.
The drug development process in the U.S. is highly regulated by the Food and Drug Administration (FDA), and it assesses safety and efficacy of the drug products to be used by the patients. Since it takes 9-12 years to bring a drug to the market, pharmaceutical companies diligently look for ways to improve the overall drug development paradigm, minimize the time to the product launch, provide timely valued medicines to patients and to decrease the duration of drug development and total cost. The conversations that take place between the Sponsor and the FDA during the development of a drug product appear to be instrumental in the drug's successful preclinical and clinical assessment and ultimate launch. Presently, it is unclear which types of interactions between the Sponsor and the FDA may be the most impactful to the successful development of a product. Therefore, it would be ideal to understand optimal interaction strategies between the Sponsor and the FDA and proactive approaches the Sponsor could undertake to improve the robustness of their internal portfolio development.
The Lilly Regulatory Affairs (Lilly-RA) Team Master's Project (TMP) team was asked to investigate the impact of formal and informal interactions, in the pharmaceutical industry, between the Sponsors and the FDA from 2009-2014 (last 5 years) by focusing on successful submissions of the New Drug Applications (NDAs) and new Biologics License Applications (nBLAs). To accomplish this objective, the Lilly-RA team: performed literature research on current FDA guidance's; devised and launched an industry-wide survey; interviewed experienced industry experts in the field of US-regulatory affairs; and, gathered publicly available documents. Upon consolidating the data from this research, the team assessed the industry's best practices. Ultimately, the team made recommendations to Lilly which describe the optimal interactions between the Sponsor and the FDA as well as the timing of these interactions to improve successful drug development.
Gilead Sciences
Establishment of a Capital Project Management Process for the Engineering Team
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead was founded in 1987 in Foster City, California. Over the past 25 years, it has grown to become one of the world's largest biopharmaceutical companies, with approximately 6,000 employees across five continents. Gilead has a portfolio of products and a pipeline of investigational drugs directed at therapies for HIV/AIDS, liver diseases, serious respiratory and cardiovascular conditions, cancer and inflammation. The Gilead site in San Dimas, one of the three manufacturing sites owned by Gilead, is a 200,000 square foot facility.
The San Dimas operation supports manufacturing, filling, packaging and labeling for a variety of products representing over 70% of Gilead's products destined for the "Americas". To support these operations, the engineering department at San Dimas, manages capital projects ranging from $3,000 to over $40 million using different management tools. Unfortunately, Gilead's current capital management approaches, adapted from the chemical industry, do not address pharmaceutical industry specific requirements such as aseptic manufacturing. In addition, the lack of a uniform predefined business process may introduce capital management errors which can lead to extended project timing and increased costs.
The Gilead TMP team was responsible for designing a 'Business Process' to enable the planning, prioritization, management, monitoring and evaluation of all capital projects at San Dimas. Additionally, the team was responsible for creating documentation including SOPs, guidelines and templates to support the capital process. To achieve these objectives, the team identified industry best practises for the capital project management process through literature review and input from key stakeholders. The team was able to establish a standard 'Business Process' tailored specifically for projects at San Dimas. 32 key documents for engineering and project management aspects were identified and developed to support the implementation of these processes. After launch of the process, Gilead, San Dimas should be able to adopt a streamlined approach to all its capital projects, leading to significant savings in terms of time and money. In the future this process may potentially be expanded to other sites at Gilead.
Gilead Sciences
Commercial Solutions to Improve Operations Efficiency
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Its focus is to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and investigational drugs includes treatments for HIV/AIDS, liver diseases, serious respiratory and cardiovascular conditions, cancer and inflammation. Gilead has several manufacturing facilities. Gilead's San Dimas facility is a sterile-fill facility which is responsible for the manufacturing of an antifungal agent, AmBisome®; the packaging and labeling of Gilead's antiviral products; and, the distribution of products to the America's and the Pacific Rim.
Pharmaceutical manufacturing processes are strictly regulated and accurate documentation is of paramount importance. Every step in the manufacturing process must follow established protocols. Documentation, during the manufacturing process, provides a summary of real-time events and confirms all validated processes were carried out according to specifications. Currently, Gilead's San Dimas facility has highly manual methods of documenting manufacturing processes. Key documented processes include data entry by shift leaders to account for labor allocation and the compilation of FDA-mandated batch records. Each of these processes is manually carried out by employees. While the San Dimas' manual documentation methods are sufficient to ensure that their products meet FDA standards, their manual documentation methods do not provide management the level of visibility needed to track and assess performance and overall equipment efficiency (OEE).
The Gilead Operational Excellence TMP team was tasked with understanding data gathering systems currently in place in the manufacturing department at the San Dimas facility. Further, the team was asked to recommend improvements or to recommend new systems for Operational Equipment Effectiveness (OEE) studies which would include the analysis of labor and process tracking. After analyzing the current data gathering systems, they identified equipment, process and people tracking needs and prioritized them in the form of a user requirement specification list (URS). A comprehensive search for commercial OEE solutions was performed which identified the top options. Eventually, the team identified solutions for high, mid, and low tier automated options as well as an improved manual option. These recommendations were followed by a SWOT analyses of the solutions to evaluate how well they meet San Dimas's needs. Finally, the team provided an implementation plan for the improvement/new system in the facility.
Gilead Sciences
Analysis of the Pharmaceutical Industry's Approach to Measuring and Controlling Subvisible Particulates in Parenteral Drug Products
Since 1987, Gilead Sciences has worked to discover, develop, and commercialize medications in order to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need. In just over 25 years, Gilead has become a leading biopharmaceutical company with a portfolio of 16 marketed products, a growing pipeline of investigational drugs and approximately 5,800 employees in offices across five continents. Gilead Science's primary areas of focus include HIV/AIDS, liver disease, and serious cardiovascular, metabolic, and respiratory conditions. Gilead's office in Oceanside, California is responsible for the clinical manufacture and process development of biologics candidates in preclinical, Phase 1 and Phase 2 testing.
The Gilead Particulates TMP was asked to perform an in depth analysis of the biopharmaceutical industry's efforts to use the characterization and quantitation of subvisible particulates as a tool to control the quality of biological drugs. The size and count of protein particle aggregates within biopharmaceutical formulations is a major quality concern which can negatively impact safety and/or efficacy of drug products. It is thus important to carefully monitor and characterize these particles. The current regulatory size limit for particles in formulation is 10 microns, as defined by FDA and ICH guidance. However, recent research has shown that this standard is not sufficient because of the prevalence of subvisible particles below 10 microns in size.
The aim of this project was to assess the advancement in regulatory and industrial standards, as well as in technologies used to monitor these subvisible particles (SVPs) in parenteral drug products - within the size range of 0.1 to 10 microns. Through in-depth literature research and interviews with key opinion leaders (KOL) within academia, industry, the FDA, and commercial vendors, the team gained insight into the progress of regulatory standards and identified the latest technologies that are most suitable for use in the surveillance of SVPs. The results of this study were compiled into a final report, which was submitted to the team's corporate liaison at the conclusion of the project.
Life Technologies
Understanding Molecular Diagnostic Testing Laboratories' Needs and Decision-making Process
Life Technologies Corporation (Life Tech), now the Life Science Solutions Group of ThermoFisher Scientific, is a global biotechnology business dedicated to improving the human condition. Life Tech provides a wide variety of tools designed to assist the life science community and is a global leader in genetic analysis through its real-time PCR (qPCR), capillary electrophoresis (CE) and next generation sequencing (NGS) platforms.
Molecular diagnostic labs face difficult decisions regarding which platforms to choose for testing of different diseases (e.g. cancer, inherited diseases, etc.) and clinical indications (e.g. screening, diagnosis, staging, therapeutic choice, etc.). These decisions are further complicated by an industry that is undergoing drastic changes including the introduction of new technology and a complete overhaul of the reimbursement system. This Team Master's Project aimed to better understand the needs and the decision-making process of diagnostic testing laboratories regarding qPCR, CE, and NGS platforms.
In order to understand how these laboratories make decisions, the KGI team conducted extensive research. The team began by consulting secondary sources such as scientific literature and market research reports to gain an understanding of the industry. This knowledge was used to structure interviews with key opinion leaders, which provided the team with a qualitative understanding of their thought processes. Based on these results, the team constructed and administered a survey to labs across the country to obtain actionable, quantitative data. These results helped the team develop a strategy to guide Life Tech in their efforts to effectively market these platforms to the most applicable sectors of the molecular diagnostics industry.
Design of a Portable Device for the Detection of Soil Pathogen
Monsanto is a sustainable agricultural company. Founded in 1901, Monsanto has been at the forefront of many scientific advancements in the agricultural industry. Monsanto is devoted to delivering agricultural products that support farmers all around the world. Current work at Monsanto is focused on increasing yields in core crops with a combination of advanced plant breeding, biotechnology, and improved farm management practices.
As plant diseases lead to significant annual crop losses, disease management strategies are an important element of Monsanto's goal to increase crop yields. This requires the accurate detection and monitoring of the presence of pathogens in the field. Current methods require samples to be transported to a centralized lab. Monsanto would like to develop a method for pathogen detection that can be used in a field setting. This would reduce the time and cost of detection and allow a more immediate response to a crop disease.
The Monsanto TMP team developed a method that can be used to detect a fungal pathogen in a field setting. To achieve this objective, the team identified various gold standard protocols designed for a lab setting, modified the procedures so that they can be performed on site with minimal training and equipment, and tested their performance. Ultimately, the Monsanto TMP team used a pre-existing instrument to develop a device which permits sample extraction and DNA purification that is coupled to target sequence amplification and quantitative detection on.
National Science Foundation Partnerships for Innovation grant
Diagnosing Ventilator Associated Pneumonia through Analysis of Volatile Organic Compound Biomarkers
The National Science Foundation (NSF), under its "Partnerships for Innovation" (PFI) program, provides funding for collaborations between academic institutions and small companies, to facilitate the translation of academic discoveries into novel products. This TMP team is working on an NSF-PFI funded project involving Keck Graduate Institute (KGI), Pomona College, and four small business partners: Tanner Research, Claremont Biosolutions, Lambda Solutions Inc, and Synedgen. The goal of this project is to develop and market a device that will allow for the early non-invasive diagnosis of Ventilator-Associated Pneumonia (VAP) through analysis of Volatile Organic Compound (VOC) Biomarkers.
Patients on ventilator support are frequently colonized with pathogenic bacteria that grow as biofilms inside the endotracheal tube. However, the presence of such biofilms does not necessarily lead to active pneumonia. The gold standard for VAP diagnosis therefore involves quantitative culture of a bronchoalveolar lavage sample, which is highly invasive and involves long turnaround times, thus leading to high costs, presumptive treatment prior to confirmed VAP diagnosis, and over-use of antibiotics. The overall goal of the NSF-PFI project is to enable early, noninvasive, differential diagnosis of VAP by measuring changes in VOCs exhaled by patients on mechanical ventilator support.
To identify unique VOC signatures that can differentiate bacteria present as biofilm versus infectious, planktonic form, the team developed a setup to grow bacterial biofilms and collect emitted VOCs, followed by analysis via GC-MS. Through literature searching and bioinformatics tools, the team investigated the scientific background and identified differentially regulated metabolic pathways that may be involved in production of unique VOC signatures.
The partnering organizations of this NSF PFI project are developing a device, consisting of a disposable sample collector, and a compact instrument, that can be used to identify VOC signatures from the exhaled breath of mechanically ventilated patients. To better understand how this device could be integrated into current clinical practice, the team is conducting primary user research to identify unmet needs and clarify product requirements. Furthermore, the team is analyzing the competitive landscape and market potential, and is identifying potential strategic partnerships. By developing a preliminary commercialization plan, the team aims clarify alternative paths for market entry.
NuSil Technology LLC
Investigating Novel Market Opportunities for Silicone Drug Delivery Devices in Women's Health
NuSil is the leading global manufacturer of medical grade silicone. Founded in 1979, NuSil is a privately held company headquartered in Carpentaria, California. Notably, with approximately 400 global employees, NuSil has additional facilities located in California, Texas, and France. The company focuses on the manufacturing of silicone compounds for the healthcare, aerospace, electronics, and photonics industries. The healthcare division is further divided into long-term and short-term implantable silicones, skin care, and drug delivery.
During phase I of the NuSil TMP project, the team was assigned the task of identifying novel commercial opportunities for silicone drug delivery devices. To complete this task, the team evaluated areas of women's health, wound healing, and antimicrobials. For each of these market opportunities, the team investigated market size, current research, competing biomaterials in addition to the intellectual property surrounding the use of silicone in each of these defined markets.
Upon the identification of women's health as the most promising commercial opportunity through secondary research and KOL interviews, the team was tasked with identifying strong opportunities in women's health. We successfully characterized over 30 disease indications in women's health, and ranked them according to market opportunity. The top four disease indications were the selected for further market research analysis. The team's analysis included areas ranging from unmet clinical need, disease prevalence and demographics, adoption rates, socio-economic analysis, technical feasibility, regulatory pathways, IP considerations and risk management. Ultimately, the NuSil TMP team produced an abbreviated business plan, which NuSil can use as a tool for the identification of new investment opportunities.
30 Years Since the Orphan Drug Act: A Comprehensive Database and Current Trends
The orphan drug act (ODA) was passed in 1983 to encourage the development of drugs aimed to treat rare diseases that affect fewer than 200,000 Americans. Some of the incentives under this act include market exclusivity for the drug maker, tax/financial incentives and expedited review by the FDA. Given the increasing cost of developing large market 'blockbuster' drugs and breakthroughs in the understanding of the molecular basis of disease progression, there is a rapidly growing interest in the development of drugs designed to treat rare diseases.
Pfizer, the world's largest pharmaceutical company in revenues, is currently exploring the rare disease space which is currently dominated by biotech companies. Pfizer's current diversified global health care portfolio includes medicines, vaccines, nutritional products, and many of the world's best-known consumer products. To help guide Pfizer in making informed decisions in pursuing orphan drug development, a comprehensive centralized resource of all orphan designations since the passing of the ODA was developed. The database will additionally serve as a guiding resource for patients and caregivers.
The goal for this team was to create a database which- includes all orphan drug designations (current as of May 2014), with associated disease area classification, stage of development, incidence/prevalence numbers, support group and sponsor information. Within the database there are 3000 plus orphan disease designations. Each designation was classified into major disease focus groups and further sub classified into specific disease therapeutic areas. The staging of development information for therapeutics in this area was derived from clinicaltrials.org. Support group information and incidence/prevalence data were obtained from reliable federal and state websites and peer-reviewed journals. A user-friendly front-end application to analyze and filter the database on the disease area, designated drugs, phase of development, etc. was also developed. By using the developed database, the team analyzed historical and current trends within the data to determine opportunities and areas of need for various rare disease classifications.
Raptor Pharmaceutical Corp.
Mapping the Clinical Landscape of Huntington's Disease
Raptor Pharmaceuticals Inc. is a publicly traded biopharmaceutical company that develops and commercializes therapeutic drugs for rare inherited diseases. The company was founded in 2005 by former executives from Biomarin Pharmaceuticals Inc., and they have been actively pursuing the development of multiple drugs in several disease indications. Their current lead product is a small molecule therapeutic known as Procysbi® (delayed release cysteamine bitartrate), which was approved for the treatment of nephropathic cystinosis in April 2013. Raptor is currently seeking to expand the utility of this active ingredient, RP103, into other potential indications such as for Huntington 's disease (HD).
In February of 2014, Raptor reported the completion of an 18-month Phase 2/3 clinical trial conducted by the Centre Hospitalier Universitaire d'Angers (CHU) in France, which indicated that the therapeutic administration of RP103 attenuated the total motor decline of HD patients. The current Standard Of Care (SOC) for HD management aims to treat chorea, one aspect of the motor decline experienced by HD patients. Given that there are currently no drugs that slow the disease progression, the CHU trial results indicate a promising potential for this first-in-class drug. In order to streamline the development and potential commercialization of RP103 for treatment of HD, the team focused on identifying signatures of HD diagnosis, disease progression and treatment outcomes.
The project was divided into three phases. In Phase I, the team conducted an extensive literature review in order to establish the landscape of HD. This was accomplished by curating published data on HD pathogenesis, patient Quality Of Life (QOL), clinical trials, current SOC and alternative therapies. Additionally, this data was used as a basis of information for the next project phase. Phase II focused on designing questions for patient and Health Care Provider (HCP) surveys, which were conducted by a contracted market research firm. These surveys helped identify patient referral pathways, HD diagnosis protocols and unmet clinical needs through consistencies and discordances among primary and secondary research. In the final phase, the team identified key opinion leaders (KOLs) using quantitative weighting measures, and began to address the clinical need for HD patient outcomes research by utilizing a proprietary insurance claims dataset. It is expected the output from this TMP will give Raptor insights into signature issues associated with HD treatment and economics, and support the marketing strategies for RP103.
Evaluation of continuous bioprocessing: industry best practices; available equipment; cost of goods; and, plant capacity for production of monoclonal antibodies and Fc fusion proteins
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and rare inflammatory conditions. Additionally, Regeneron has product candidates in development for other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.
The Regeneron TMP team was asked to evaluate aspects of continuous bioprocessing including: 1) available types of equipment; 2) the impact of this technique on cost of goods; and 3) a continuous bioprocessing plant's capacity for the production of monoclonal antibodies and Fc fusion proteins. As part of the TMP team's effort, an initial survey was conducted to determine industry trends and best practices regarding the use of upstream and downstream continuous bioprocessing. Additionally, a second survey was conducted to evaluate the equipment used in continuous bioprocessing. The project culminated in the production of a final report detailing the global cost of goods and associated plant capacity analysis related to the implementation of continuous bioprocessing technologies.
In order to complete the initial survey related to industry trends and best practices centered on continuous bioprocessing, the Regeneron TMP team constructed and deployed a digital survey to key opinion leaders in the pharmaceutical industry. The second survey focused on making direct contact with equipment manufactures and vendors with knowledge of state-of-the-art bioprocessing technologies, in order to document the available equipment for continuous processing applications. Using a Greenfield facility as a basis, the team's final project task was to perform a cost of goods and plant capacity assessment of continuous processing versus fed‐batch processing at a commercial scale. The results and the analysis of the first survey were conveyed to Regeneron in early January of 2014, and results of the second survey and the Greenfield analysis were presented to Regeneron in early May 2014.
Sarepta Therapeutics
Evaluation of the Market Potential and Development Feasibility of Seven Rare Disease States
Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by life-threatening rare and infectious diseases. The company's long-term vision is to become a leading, independent biotech company capable of sustainably developing a pipeline of breakthrough therapeutics and bringing them to the patients who need them. To accomplish this vision, Sarepta has a unique phosphorodiamidate morpholino oligomer (PMO) technology at its disposal that is uniquely versatile, allowing for the development of a range of therapeutic candidates that target different types of RNA.
Sarepta's pipeline currently includes its lead clinical candidate, eteplirsen, for the treatment of Duchenne muscular dystrophy as well as potential treatments for influenza and Marburg hemorrhagic fever virus. Sarepta is interested in adding candidates to its pipeline that are based on its platform PMO technology. However, Sarepta has devoted its resources to gaining approval for its current pipeline and hasn't formally evaluated which disease state the company should pursue next.
The Sarepta TMP team was tasked with evaluating the risk/benefit profiles of 7 disease states to determine which indications would provide the highest return on investment (ROI) while limiting risk. To accomplish this task, an IP landscape and competitor analysis was conducted to look for areas with freedom to operate. Next, the feasibility of conducting and designing successful clinical trials that would support a regulatory pathway with limited clinical endpoints was analyzed. Finally, a financial analysis that compared the potential market opportunity to the costs of development of a therapeutic for each disease was completed to ascertain ROI. In support of the original objective, a report which included a high level comparative analysis of the risks and benefits of developing a therapeutic was performed for each of the variables being examined to form the prioritization strategy for Sarepta.
Sigma-Tau Pharmaceuticals Inc.
Epidemiological Landscape of cerebrotendinous xanthomatosis (CTX) and Recommendations for the Implementation of a Newborn Screening Test
Sigma-Tau Pharmaceuticals is dedicated to helping patients affected by rare diseases. The FDA defines a rare disease as a disease that affects fewer than 200,000 individuals in the United States. Sigma-Tau's core belief and dedication is that the study of rare diseases should be an integral part of its research activity. Consequently, Sigma-Tau has chosen to specialize in these diseases by discovering novel therapeutics to help patients suffering from these rare conditions.
Sigma-Tau Pharmaceuticals is in the process of exploring and expanding their rare disease product profile for cerebrotendinous xanthomatosis (CTX). Unfortunately, there is no current standardized screening method in the United States for CTX. Consequently, without proper disease detection, CTX patients can remain undiagnosed or misdiagnosed until their disease state has progressed. Sigma-Tau is interested in generating a road map for the inclusion of CTX in newborn screening. The establishment of a standard for the CTX screening of newborns will help patients by providing a more timely diagnosis of disease, provide patients with earlier therapeutic intervention and increase the market opportunity for Sigma-Tau Pharmaceutical's CTX-related products.
The Sigma-Tau TMP team was given two main goals: 1) gain an in-depth understanding of the epidemiology of CTX; and, 2) generate a road map for the possible adoption and implementation of a test for CTX in the existing newborn screening panel. To accomplish these objectives, the team performed a comprehensive literature search and interviewed Key Opinion Leaders of CTX to understand unmet clinical needs associated with CTX diagnosis and treatment. The team then synthesized collected information to produce an overview of CTX diagnosis within the United States and to develop a strategy for the newborn screening of CTX. In addition, the team identified diseases mechanistically related to CTX and compiled an Orphan Drug Application (ODA) involving a promising new indication for one of Sigma-Tau's CTX-related products. This ODA was provided to Sigma-Tau for possible submission to the FDA. Upon project completion the TMP team provided Sigma-Tau a CTX status report which included: all available CTX epidemiologic and diagnostic data; identified current unmet clinical needs associated with CTX; explored and identified the role of patient advocacy groups within the CTX community; provided recommendations to increase CTX awareness; and, recommendations regarding the implementation of a newborn screening test for CTX.


text:
ABC News' Devin Dwyer reports:
It seems freshman Republican Sen. Scott Brown's challenge to President Obama for a friendly game of two-on-two basketball still stands – and now with the goal of raising money for charity.
Ayla Brown, the senator's daughter and Boston College basketball star, says she and her dad are serious about a game of hoops with the president and believe it could help raise awareness for earthquake relief in Haiti.
"I think it'd be really fun… maybe put a basketball court in the White House somewhere…. I was thinking why not charge admission — it'd be a really good game knowing me and my dad, we're very competitive — and give all the proceeds to Haiti," she in an appearance on ABC News NOW.
Following his upset electoral victory last month,Sen. Brown told supporters he spoke with Obama and said, "Mr. President, I know you like basketball, so I tell you what, how about you pick your best player, I'll take Ayla and we'll take you on two-on-two."
No word yet from the White House on the so-called "basketball summit."
Ayla Brown also told ABC that she spent Valentine's Day with her teammates despite her father's now infamous public disclaimer at a victory rally that his daughters are "both available."
"He definitely made that statement of me being 'available' and we just laughed about it afterwards – we're like what were you thinking? I didn't realize how big of a thing it was going to be," she said with a chuckle.
Watch the full interview HERE:

subset: commoncrawl


text:
Bowburn's bad hair day (From The Advertiser Series)
Send us your pictures, video, news and views by texting NORTHERN ECHO to 80360 or email us
Bowburn's bad hair day
11:29am Friday 16th May 2014 in News
USUALLY a bad hair day is an unwelcome development.
But not for children at Bowburn Infants and Nursery School, in Bowburn, near Durham, who donned bizarre hairstyles to raise money for the North East Autism Society.
Each child taking part made a small donation to the cause.
Trish Fay, from the school, said the school was a riot of colour for the day.
Comments are closed on this article.


text:
Nepenthes attenboroughii
Nepenthes attenboroughii
Comprehensive Description
Nepenthes attenboroughii is a montane species of insectivorous pitcher plant. It is named after the celebrated broadcaster and naturalist, Sir David Attenborough,[1] who is a keen enthusiast of the genus Nepenthes. The species is characterised by its large and distinctive bell-shaped lower and upper pitchers and narrow, upright lid (Robinson et al, 2009).
Conservation and Management
Conservation Status
Robinson et al. (2009) assess this species as CR (Critically Endangered) according to the World Conservation Union (IUCN) Red List Criteria B2ab(v) (IUCN, 2001). They base their assessment on the species' limited distribution and its vulnerability to poaching.
Diagnostic Description
Overall Nepenthes attenboroughii is a terrestrial upright or scrambling shrub.(Robinson et al, 2009)
Stem The stem, which may be up to 3.5 cm thick, is circular in cross section and attains a height of up to 1.5 m.(Robinson et al, 2009)
Leaves The leaves are coriaceous and sessile or sub-petiolate. The leaves of rosettes are up to 30 cm long and 10 cm wide, whereas those of the scrambling stem are up to 40 cm long and 15 cm wide. The leaves are oblong to elliptic, obtuse at the apex and shortly attenuate at the base, clasping the stem by approximately two-thirds of its circumference and becoming decurrent for 2-3 cm.(Robinson et al, 2009)
Pitchers Nepenthes attenboroughii produces some of the largest pitchers in the genus, sometimes exceeding those of typical N. rajah in size, but is not known to have exceeded the size and volume records set by that species. The lower pitchers are brittle and campanulate (bell-shaped), up to 30 cm tall and 16 cm wide and emerge from tendrils that are 30-40 cm long and 4-9 mm in diameter. The tendrils are obviously flattened towards the leaf, making them almost semi-circular in cross section.(Robinson et al, 2009)
The upper pitchers are similar to the lower pitchers, but generally infundibular, to 25 cm tall and 12 cm wide.(Robinson et al, 2009)
Inflorescence Nepenthes attenboroughii has a racemose inflorescence up to 80 cm long. The male flower spike bears approximately 100 pedicellate flowers on a rachis up to 45 cm long and is recorded to bifurcate on occasion. The flowers lack bracts and produce red tepals that are broadly ovate with an obtuse apex.(Robinson et al, 2009)
The female inflorescence is shorter, to 65 cm long, never bifurcates, and bears up to 70 densely arranged flowers on a compact rachis up to 20 cm long. The tepals are brown to purple, ovate, and have an acute apex.(Robinson et al, 2009)
The type specimen of N. attenboroughii was collected on the summit of Mount Victoria, an ultramafic mountain in central Palawan, the Philippines.(Robinson et al, 2009)
This species is known only from the summit area of Mount Victoria, Palawan, to which it is endemic. There, it grows among shrubs 0.8-1.8 m tall in relatively scattered populations of plants on rocky, ultramafic soil. It is not sympatric with other Nepenthes species.(Robinson et al, 2009)
Trophic Strategy
Carnivory The pitchers of N. attenboroughii are open to the elements and thus often completely filled with fluid. This fluid is viscous in the lower part of the pitcher and watery above, forming two fractions that do not mix. The upper fraction supports populations of pitcher infauna, particularly mosquito larvae, and the pitchers of this species may benefit from both the usual capture of prey as well as the detritus produced by organisms living within the pitcher fluid.(Robinson et al, 2009)
Evolution and Systematics
Systematics and Taxonomy
Nepenthes attenboroughii is closely related to the Palawan species, N. mantalingajanensis and N. mira, to N. peltata from Mindanao, and to N. rajah from Borneo.(Robinson et al, 2009)
The stated relationship of this taxon with species from Borneo and Mindanao agrees with observations made in the description of N. mira,(Cheek and Jebb, 1999) and is further supported in the type description of N. attenboroughii by paleogeographical evidence. Based on this evidence, the authors reason that these species, predominantly found growing on ultramafic soils on Palawan and Mindanao, are likely to have arisen as a result of the radiative speciation of a common ancestor in Borneo.(Robinson et al, 2009)


text:
Morning Commute Crashes On Slippery Roads In Warren
Thursday, January 30, 2014 • 12:24pm
WARREN, NJ - According to a report issued by the Warren Township Police Department, two crashes took place during the morning commute on Monday, Jan. 27.
At 6:12 a.m., a vehicle driven by Raymond Tung of Warren left the roadway on King George Road close to the entrance to Route 78. No injuries were reported and no summonses were issued. AAA towed the vehicle.
A little more than an hour later at 7:27 a.m., a two car accident occurred on Hillcrest Road close to that entrance to Route 78. A vehicle driven by Jason Stiner of Berkeley Heights rear-ended a vehicle driven by Todd Brugmans of Warren. No injuries were reported and no services were needed. Stiner was issued a summons for failure to produce the vehicle's registration.


text:
It will be a busy year for the alternative-fuel industry, thanks to the reinstatement of several biofuel-related tax incentives, said Rick Price, executive director of Pittsburgh Region Clean Cities. The tax-credit extensions are "going to help move people that have been teetering on the edge," Price said. "This year's going to be very busy going out and reinvigorating those people," he stated.
View Full Article in:
American City Business JournalsPublished in Briefs:


text:
Working with the CommunityHalpenny Travel and its team have worked closely with the local community over the past 90 years. Halpenny Travel & Rural Transport ProgrammeHalpenny Travel is heavily involved with Louth Linx (link to http://www.louthlinx.com/ ) with the provision of services under the Rural Transport Scheme. The purpose of this scheme is to give older people in particular a service which brings them door-to-door from their home to town.
Halpenny Travel & Local clubs and SchoolsHalpenny Travel also work with several local community groups and societies such as our local Athletics Club, Karate Club, GAA clubs in our surrounding areas and also over 50% of the schools in the Blackrock and Dundalk area. |


text:
tomas c said about: BRICE CATERING LTD
Words cannot express how wonderful you and team were for Hugo's 21st birthday party. My mother is 93 and my great niece is 5 and everyone loved the delicious buffet....
Added September 2014
Simon S said about: HUNTS ANTIQUES
Wow what a place, could spend all day here, visited today for the first time with the family and we all found lots we liked, the staff are really freindly and very helpful. Looking forward to visiting again very soon.
Added June 2014
tara s said about: Quantex Security and Fire Specialists
had a full business alarm system fitted by Quantex, they were professional, couteous and polite. nothing was too much trouble and they explained everything about the process, timing and cost along the way....
Added June 2013


text:
@MrsPramm - Honestly, social worker jobs in any sphere are always going to be dealing with people who are scared and sad. The good thing is that sometimes you can help. The worst is that often you can't do all that much.
This can be particularly devastating in the medical field, where there is so much frustration involved with people not getting the treatment they need and deserve because their insurance doesn't cover it, or whatever. It's definitely not a job for someone who is very sensitive or who crumbles under pressure, because when you are advocating for the mental health of patients you will often find yourself without many allies.
But someone has to do it and when things do get done they can be very satisfying.


text:
Pelican 9430 Remote Area Lighting System - PCL-9430
Note that the displayed specifications are based on the currently selected product options on the right. To see the complete list of specifications complete your selection of product options on the right.
Nsn | 6230-01-569-9643 | 6230-01-570-0962 |
Product Name | Pelican 9430 Remote Area Lighting System |
Certificates | RoHS |
Weight | 22.05 |
Weight With Batteries | 352.80 |
Special Features | Tested Lumen Value: 3000 (High), 1500 (Low) Burn Time: 8 hours (High), 15 hours (Low) Battery Type: 12v Rechargeable, Sealed |
Estimate Shipping
This shipping estimate is based on this product only and does not include other products which may be in your shopping cart. Also note that the shipping weight can change based on the currently selected product options on the right.
Pelican Products, Inc. warrants its AALG products to the original purchaser against defects in materials and workmanship for 1 year from the date of purchase. All warranty claims of any nature are barred if the product has been altered, damaged or in any way physically changed, or subjected to abuse, misuse, negligence or accident.
All returns and exchanges are to be made within 10 days of purchase.
Merchandise returns must be shipped, pre-paid, at the customer's expense. All returned items must be in "as-new" condition, in their original packaging, with all accessories enclosed. The original packing slip must be included and the Return Merchandise Authorization (RMA) number must be visible on the outside of the shipping package. To obtain a RMA number, call our customer service department at 888.515.5255. You must be able to provide the following information: the quantity and item number of the product to be returned, the date of purchase, the invoice number, and the cost of the item. Discrepancies or missing information may result in delays or refusal of your refund. Merchandise returned to Cases By Source, Inc. without a RMA number will not be accepted. The issuance of a RMA number does not guarantee that a credit will be issued.
If part of a product becomes defective, the entire item must be returned for credit or replacement within 10 days of the invoice date. A packing slip—with the item number(s) and a description of the defect—must be included in the package. At its discretion, Cases by Source, Inc. will repair or replace defective goods. Please Note: Following repair or replacement, defective goods will be returned to customers in the same box in which they were received by Cases By Source, Inc.
All merchandise returns—defective or otherwise—are subject to thorough inspection by a Cases By Source, Inc. representative. Merchandise credits are issued at the company's discretion, based on the aforementioned requirements and instructions. A $25.00 re-boxing fee will be charged for credited products not returned in the original manufacturer's packaging.
All returned items are subject to a 15% restocking fee.* Some exceptions applied
Refunds will not be issued for custom case orders.
Refunds exclude shipping charges for returned items that are not defective.
Please allow 2-4 weeks for refunds to be processed and credited to your account. If your order was charged to a credit card, we will need your card number to process the refund (Orders placed online do not provide full disclosure of the card information.)


text:
Ask Queen Ashe
Senior Member
Ask Talon
Dear Ashe, I am rather interested, what are your thoughts on Noxus? Rather, what are your thoughts on the Noxian champions? ~Talon
Where are you getting your arrows from? There's no ****ing way you could be standing at your tower shooting 1 arrow per second at minions without running out of arrows! BTW: How many arrows do you bring, and what would you do if you were out of arrows?
Ask Shyvana
Prophesy can be a double edged sword, Queen Ashe. For all we know, the prophecy of Sejuani uniting Freljord could be her death bringing the rest of the Winter's Claw under your rule. Because of that, I pay no mind to prophecy. They are simply word games meant to control the foolish. ...though it occurs to me that you take the prophecy seriously. I of course mean no offense. I'm sure Sejuani will be an important political figure in history. It's simply my advice to you that you don't take the prophecy too literally. If you don't like the way the prophecy tells the future, force it to unfold differently. While we're on the subject of Sejuani, though, I have to ask: was there ever peace between you two?
Ashe, I must agree with Shyvana on her thoughts about prophesy. The past cannot be changed and the future is a distraction. There is only now. ~Talon
November Anon
Your Grace, What are your thoughts on the League permitting Sejuani as a champion? Do you agree with their decision to let her fight you on the Fields of Justice, alongside the other champions? Also, barring the decision to solo middle lane, who is your favorite laning partner, and why?
Dear Ashe, Been wondering, how is your relationship with Volibear and the Ursine since his induction into the League? Outside the League, are you in your usually clothing and gear or in your royal garb?


text:
Claiming a Prize
Congratulations on your win!
Now, if you haven't already signed your winning ticket, make sure to complete the Claim Form on the back.
Prizes up to $200 are automatically validated when scanned by a lottery terminal, and Retailers are required to pay these prizes, or to make arrangements to do so. However, Retailers are not obligated to pay prizes over $200. If a ticket wins $200.01 or more, the Retailer can cancel the validation, and direct you to claim your prize at another Retailer or from a prize office.
Stores or franchises may choose not to redeem prizes of over $200 for a variety of reasons, which may include security concerns about keeping large amounts of cash on the premises. Lottery Retailers are independent businesses, and we respect their right to make such decisions.
Prizes up to and including $1,000 may be claimed at a Lottery Ticket Centre offering this service. Check with the Retailer before having the ticket checked to ensure they have enough money to pay the prize.
For prizes over $1,000 and merchandise prizes, WCLC has Prize Payout Offices located in Calgary (up to $9,999.99) or St. Albert, Alberta; Regina or Saskatoon, Saskatchewan and Winnipeg, Manitoba. Prize claims of $10,000 or more require an appointment.
To make sure your winning experience is a memorable one, please contact us. Call Customer Care at 1-800-665-3313 during regular business hours, Monday to Friday, for instructions on claiming your prize.All prizes can also be claimed by mailing tickets to:
Western Canada Lottery Corporation
Prize Payout
10th Floor, 125 Garry Street
Winnipeg, Manitoba R3C 4J1
Note: Print your name, address, and daytime telephone number in the Claim Form on the back of the ticket. All risks of sending tickets through the mail remain with the player. Don't forget to claim your prize before the expiry date specified on the back or front of the ticket.


text:
Lansky Firefighter's Battle Axe, 15" Overall Length, Leather Sheath - AX-911
Part Number: | LSAX911 |
Manufacturer: | Lansky Sharpeners and Knives |
Retail Price: | $74.99 |
Our Price: | $51.95 |
You Save: | $23.04 (31%) |
Calculate Shipping |
LSAX911: Firefighter's Battle Axe
Lansky Sharpeners
Designed by Lansky Knife & Tool along with the close advisement of numerous Professional Firefighters from concept through final production, the Fireman's Battle Axe is designed to be the multi-purpose "sidearm" of choice for Professional and Volunteer Firefighters alike.
- Gas Valve Wrench
- Tool is load bearing to 600 lbs.
- Hose Wrench
- Handle is insulated up to 10,000 Volts
- Impact Tool
- Pry Bar
- Blade Length: 5"
- Blade Steel: 1075 Tool Steel
- Overall Length: 15"
- Handle Length: 7-1/4"
- Sheath Material: Leather
- Weight: 1 lb. 12.3 oz.
UPC Code: 080999509111
Leather is known for its durability and traditional appeal. When compared to kydex it is preferred for its silence when bumped against other objects, as well as blade retention.
A nylon polymer that is lightweight and extremely durable, Zytel can be shaped and textured to provide excellent grip.


text:
We are halfway through our first month using the envelope system and doing great! I feel so good knowing that if I don't have the money on hand, I don't buy it.
Food can really take a toll on a budget, and we have money in our envelope for the rest of the month! Usually my big shopping trip at the beginning of the month wipes the grocery budget out.
This is my plan this week for the last full week of school:
Monday- Fettuccine Alfredo
Tuesday- Chicken Enchiladas
Wednesday- Ziti
Thursday- Pizza
Friday- Chicken Tetrazini
Saturday- Lasagna
Sunday-Sausage Hoagies
Extra's that I will be making for snacks and breakfast (most from my busy week last week):
What is on your menu this week?
Linked to: Menu Plan Monday
Old Fashioned Recipe Exchange
Sign up for free daily e-mails from simply things family to stay up to date.


text:
©2003-13 Cosham Baptist Church. Havant Road, Cosham Portsmouth, PO6 2QZ. Phone: 023 9232 4688. Mail Registered Charity no. 1126959
We warmly welcome you to the online home of Cosham Baptist Church. We are a Bible-believing church that desires to share the love of God to everyone.
We believe every individual is valuable which is why it would be a joy to be able to meet with you in person. A lively gathering of about 250 people of all ages meets each Sunday morning.
Come as you are!
We meet at the Baptist Church on the south side of Havant Road, in Cosham, next door to the Iceland car-park.
Please take a look around this site to find out more about us, about Cosham, or about the Christian faith.


text:
- Your Path:
- Home
- Johnny Test Foil Balloon
- Johnny Test Foil Balloon
Foil balloons make decorating for your party easy and fun. Add to a balloon bouquet or tie to the birthday child's chair for a great look! Includes (1) uninflated Foil balloon which measures approximately 18" in diameter. Pattern is printed on both sides of the balloon - may have two different images on either side. Add Latex balloons, curling ribbon and balloon weights to create a truly uplifting arrangement. Please Note: Balloons ship flat. This is an officially licensed Johnny Test product. Read More
Johnny Test Foil Balloon
- Was:
- $0.00
- Price:
- $2.99
You Save %0 OFF
- Prod ID:
- 84667
- 4.0
- 1 Reviews
Orders placed by 1pm CT usually ship same day.
You May Like
Customer Reviews
Johnny Test Foil Balloon
1 Total Reviews
- Overall Rating:
- 4.0
- Write A Review


text:
August 19, 2010
CLAIMS by US geoscientists that they have discovered the oldest known animal life have been greeted with scepticism by Australian experts.
Paleontologists such as Jim Gehling with the South Australian Museum say it is no surprise that simple sponge-like animals lived 600-650 million years ago, as reported yesterday in the journal Nature Geoscience. But they are far from convinced they are what the Princeton University team has found.
"To argue these were sponges is a difficult proposition. They look like Coco Pops, " said Dr Gehling.
Moreover, Dr Gehling said better, older fossils had been found three years ago by University of Melbourne geologist Malcolm Wallace and his team. Dr Gehling suggested that competitive pressure might have been the reason Dr Wallace's group has been unable to publish their results.
The Australian understands that one of the co-authors of the contentious paper is a reviewer for the journal Science, to which Dr Wallace's group has submitted a paper. It is not clear whether the reviewer has read the paper but Dr Wallace acknowledged that "we've had difficulties getting our results published". He preferred not to discuss Dr Gehling's suspicions. He did affirm that his group's finds were roughly 20 million years older than those reported by the Princeton team, headed by paleontologist Adam Maloof.
Along with colleagues at New Jersey-based Princeton and the Smithsonian Institution in Washington DC, Professor Maloof reported that calcified material found in limestone rocks in the Flinders Ranges of SA were probably "sponge-grade metazoans" -- simple multi-celled animals.
But Dr Gehling said the the tiny fragments described as sponges by Professor Maloof and his colleagues were poor candidates for the oldest animal honours.
Dr Gehling said Dr Wallace's team had found "definite fossils", centimetres in size. He said the Melbourne fossils came from what had been a deepwater reef, while the Princeton group's material was from what was then highly disturbed shallow water.


text: 9/9/2010 The Action Back, available in Realtree AP camouflage, is a versatile spreader constructed with aluminum, stainless-steel and plastic. The adjustable downspout and reducing inserts allow it to spread any size feed, seed, fertilizer or pelletized mineral in hard-to-reach locations. With its 35 lb. capacity, you can also attach The Action Back to your ATV to plant larger food plots or feed out shooting lanes. Or, use the optional plug-in remote accessory along with the receiver hitch attachment to fit it on larger ATV's, UTV's, Bad Boy Buggies and trucks. When you've found a spot where you want to concentrate your feeding and hunting, you can hook up The Action Back with the hanging attachment and use the plug-in digital timer to feed at the prime hunting times while you're in the stand. It even doubles as a swivel-hunting seat. The Action Back comes standard as a backpack with a push-button switch and an ATV attachment that fits all standard ATV racks. Accessories include a receiver hitch attachment, hanging attachment, plug-in remote, plug-in digital timer, and Ni-H 9-volt batteries and charger. For more, visit www.theactionback.com.


text:
The Origins of Kenya safari Holidays For several decades,Kenya safari parks have been the hunting grounds by both the white settlers and the African people. Then came the Kenya-Uganda railway that further gave access to the interior of Kenya. Cities (resting grounds) started to emerge slowly. Those were the years when hunting was a sport for the noblemen. It was a very special affair. Those expeditions were done on convoys, transporting foods and camping gears. Convoy in Kiswahili language is 'Msafara'. Some of the settlers started making income from organizing and leading hunting safari expeditions. It was a safari for the bold and chosen few. This was the origin of the modern day 'safaris' in Kenya. Safari means to Travel. While hunting is banned in, Kenya remains the number one country for safaris, and has done so well to maintain the status and as the origin of Safari. It is here that your Kenya safari holiday will take you to these wildlife parks to enjoy, and to capture memories that you will treasure for long. Kenya Wildlife safari: Wildebeest Migration Just recently, the phenomenon wildebeest migration was recognized as the Seventh wonder of the world. This natural event takes place in July – October in Maasai Mara which lies 300 kilometers south east of Nairobi. The animals move from northern Serengeti plains in Tanzania across Mara and Telek Rivers in Maasai Mara. If this is your first Kenya safari holiday, or you are hearing about the wildebeest migration first time, then relax! This article will give you real facts and eye witness occurrences on migration.. ....Read more. Natural Track is a member of Kenya Association of Tour Operators Bonding scheme that ensures the safety of your payments and your security. This is an insurance cover whose purpose is to protect your safari finances at the same time putting your safety in highest regard.
Special Safaris |


text:
There was quite a bit of buzz about Dolce de Palma when it opened last spring — everybody I ran into wanted to shove me against a wall and yak into my ear about Anthony de Palma's new paninoteca. De Palma had opened Dolce in a frighteningly eccentric location — tucked behind the railroad tracks alongside a canal, in a warehouse district on Old Okeechobee Boulevard in West Palm Beach. It was the kind of real estate that would have had backers and moneymen sweating into their Brooks Brothers; only de Palma was on his own and risking nothing more than his own butt. The restaurant was the single bright little beacon on a gloomy, deserted street, rough enough that there were bits of rebar and piles of dirt in his minuscule parking lot.
Still, de Palma wasn't entirely crazy. Dolce was close to Flamingo Park, probably the wealthiest neighborhood in West Palm, so it had a good chance of drawing people with money and appetites. It was hidden enough that you practically had to follow a treasure map to get there, but its removed locale gave the restaurant an insidery, exclusive air, like those unmarked, unlisted bars in Manhattan. And then it was doing weird stuff like opening at 5:30 in the morning for breakfast, dishing up paninis and gelato for lunch until 4, and serving dinner Thursdays, Fridays, and Saturdays. It was mostly the dinner everybody was talking about (not that those lunch paninis weren't delicious), particularly the homemade pastas and a small wine list of intriguing bottles.
We stopped in for dinner shortly after they opened in early summer and had a surprisingly inept meal. I don't know what was up, but the place was near empty on a Thursday night — I think there was just one other occupied table — and pretty much every dish we had was a wash. The worst of it was the short ribs ($17.95) with orzo, braised escarole, artichokes, and "smoked oven-dried tomatoes"; they tasted like somebody had poured about half a bottle of liquid smoke into the sauce. We also had a bland risotto cake appetizer ($9.95) with escargots that didn't impress my snail-loving partner and a forgettable ricotta pastiere ($6.95) for dessert. We folded our napkins and left wondering what all the fuss was about.
1000 Okeechobee Road
West Palm Beach, FL 33401
Category: Restaurant > Gelato
Region: West Palm Beach
Clearly, the new restaurant hadn't quite gotten its act together. But our experience must have been a fluke. We kept hearing raves. Six months later, Dolce has so established itself as a neighborhood favorite that it's tough to get a dinner reservation on weekends. We did score one recently and found that de Palma had expanded by setting up tables in a little outdoor courtyard — they were all full at 8:30, and the space inside, which holds only a few dozen diners, was nearly full too. The restaurant itself is darling, simple and intimate, very European in mood — there's an open kitchen where battered old pots and frying pans hang above the work stations, a gelateria near the front door, and tables set with white cloths and candles in a mirrored back room. This time, we had a marvelous meal.
And I do mean marvelous in the sense of something to marvel over. With the economy in the dumps, we could use more restaurants like Dolce: Rather than slavishly following the conventional wisdom for economic-doldrums dining (cookie-cutter American comfort food, fast-casual), de Palma has created a unique experience — selling homemade gourmet Italian cuisine in a bistro setting at prices that will keep the house full and regular customers returning. No entrée is more than $23; no bottle of wine costs more than $45 (and most are in the mid-20s to mid-30s). Add a level of personal service that makes every customer feel soothed and cosseted — de Palma makes a point of stopping by every table, and the waitresses are professional, courteous, and well-informed — and you've got a recipe that'll rise, soufflé-like, over any yawning recession.
Particularly when you consider what you get at these reasonable prices. The menu changes nightly with very few repetitions. De Palma has been known to roast whole suckling pig some nights; we found black-tip shark "gouganette" on the menu ($19) served with crab polenta and coriander/miso/truffle oil sauces. There were appetizers like handmade grilled merguez sausages with arugula and yogurt ($10), a wild mushroom and fennel tart with goat cheese fondant ($7), and a caesar salad whimsically presented by running the whole romaine leaves through a cored heirloom tomato and scattering the plate with potato-bread croutons ($8). He clearly loves to invent new recipes: A pasta called "chef's whim" ($21 for a full order) turned out to be the most beautiful gnocchi I've ever seen — fat, gorgeous, inch-wide cubes flecked with fresh thyme and rosemary and served with tiny, spicy, veal sweetbread sausages. It was a knockout.
We also ate a tender and succulent chicken involtini ($19): chicken breasts pounded thin and rolled around a savory filling of portabella mushrooms, sliced into rounds and served with a sauce of harissa and sun-dried tomatoes; this dish was supposed to be served with rapini, but they were out of it (we got asparagus instead). The only entrée we didn't much care for was a grilled sirloin steak ($23); I liked the pickled red cabbage slaw and shiitake mushrooms, bracing and sour, that came with it, but the steak itself was tough and flavorless.


text:
Start learning with our library of video tutorials taught by experts. Get started
Learn how to restore damaged photos from the Photoshop senior product manager.
Photoshop senior product manager Bryan O'Neil Hughes takes you on an insider's tour of the key photo-enhancement features in Photoshop CS6.
"I almost feel as if I am in a classroom but with the benefit of sitting at my home computer." —Christine B.
more from our members »


text:
This is something I personally would not do, but I don't have my gun surgically attached to me like some of you
I'm not talking about the one beer or glass of wine with dinner. But for instance, if you had or went to a private party, what would you do? Even if you had no intention of becoming inebriated, one drink always has the potential for becoming 6 or 7 (or more....). We would all like to think we have control even when we have a few, but given the possible horrible consequences, what would you do?


text:
Purchased a FORA.tv video on another website? Login here with the temporary account credentials included in your receipt.
Alissa Walker, editor for GOOD magazine, shares some fun and innovative ideas that could help solve some of San Francisco's biggest problems.
To download this program become a Front Row member. JOIN NOW >>
To download this program become a Front Row member.
ZOOM IN: Learn more with related books and additional materials.
Art and technique of designing and building, as distinguished from the skills associated with construction. The practice of architecture emphasizes spatial relationships, orientation, the support of activities to be carried out within a designed environment, and the arrangement and visual rhythm of structural elements, as opposed to the design of structural systems themselves (see civil engineering). Appropriateness, uniqueness, a sensitive and innovative response to functional requirements, and a sense of place within its surrounding physical and social context distinguish a built environment as representative of a culture's architecture. See also building construction.
© 2010 Encyclopædia Britannica, Inc.
Sign up today to receive our weekly newsletter and special announcements.


text: For complete online access to Vatican II Is Still News Practical Christianity Summit of the Gods Clear Philosophy Breaking the Ties That Bind "Like a Startle . . . Like a Flinch" Dialogue with a Dominican Every issue of Touchstone also contains short commentaries by our editors, notices of books you should know about, and our spirited letters section. Order issues of Touchstone at our online store. Subscribers can read issues in digital format at the NEW Touchstone digital archives! Subscribe to Touchstone today! |


text:
Florida Man Calls 911 To Request Female Deputies Have Sex With Him
According to the Hillsborough County Sheriff's Office, Joshua Basso, called 911 seven separate times between August 22 and August 24. Each time he requested that a female deputy come to his home for some sexing. We're not even sure porno script writers could come up with a such dumb idea.
Police eventually went to his home, not for sex, but to arrest him. Basso admitted to making the calls and was charged with seven counts of making false 911 calls.
This was not the first time Basso tried this stunt.
According to The Smoking Gun, back in 2009 Basso's cellphone ran out of minutes, so he decided to call the one number he knew was free: 911. He asked a 911 operator about her breasts, and wondered if she might come over to have sex with him. He also told her was masturbating at the time.
Follow Miami New Times on Facebook and Twitter @MiamiNewTimes.
Sponsor Content


text:
Posted: May 28, 2012 11:23 AM by Alan Cutler
Updated: May 28, 2012 11:25 AM
After his great performance in the SEC Tournament, UK senior third baseman Thomas McCarthy made the 2012 Southeastern Conference All-Tournament Team.
McCarthy hit .462 (6-for-13) during the three games in Hoover, Ala., helping lead UK to its best finish in the modern-era history of the tournament (1998-present). UK posted wins over Ole Miss and Mississippi State, before falling to the Bulldogs in the semifinals, 2-1 on Saturday, with MSU going on to claim the title with a 3-0 win over Vanderbilt on Sunday.
The 6-foot-2, 200-pound right-handed hitter, tied an SEC Tournament record with three doubles in a four-hit game against Mississippi State on Thursday, a 5-1 UK win. He is the first UK player to be named to the SEC All-Tournament Team since Sawyer Carroll and Chris McClendon were tabbed to the team in 2008.
McCarthy had an outstanding season hitting .309 with 19 doubles, five homers and 30 RBI, a year after hitting .411 in SEC play to earn first-team All-SEC honors. He is the first UK third baseman named first-team All-SEC since 1972.
2012 All-SEC Tournament Team
P Brian Johnson, Florida
P Jonathan Holder, Mississippi State
C Spencer Navin, Vanderbilt
1B Matt Snyder, Ole Miss
2B Casey Turgeon, Florida
3B Thomas McCarthy, Kentucky
SS Adam Frazier, Mississippi State
OF Connor Harrell, Vanderbilt; Mike Yastrzemski, Vanderbilt
OF Mason Katz, LSU; Justin Shafer, Florida
OF Demarcus Henderson, Mississippi State
DH Brian Johnson, Florida


text:
In Thy Kingdom remember us, O Lord, when Thou comest in Thy kingdom.
Blessed are the poor in spirit, for theirs is the Kingdom of Heaven.
Blessed are those who mourn, for they shall be comforted.
Blessed are the meek, for they shall inherit the earth.
Blessed are those who hunger and thirst after righteousness, for they shall be filled.
Blessed are the merciful, for they shall obtain mercy.
Blessed are the pure in heart, for they shall see God.
Blessed are the peacemakers, for they shall be called the sons of God.
Blessed are those who are persecuted for righteousness' sake, for theirs is the Kingdom of Heaven.
Blessed are you when men shall revile you and persecute you, and shall say all manner of evil against you falsely for my sake.
Rejoice and be exceedingly glad, for great is your reward in Heaven.
Bonus Link for those who have a free hour: Zelenka: Missa Omnium Sanctorum (Mass for All Saints)


text:
- dotTech - http://dottech.org -
dotTech Promo: Free mediAvatar DVD Converter! [72-hours only]
Posted By Ashraf On December 15, 2010 @ 12:00 AM In dotTech Promotions,Freebies | 36 Comments
[1]Update: This promotion is now over. Sorry to those that missed it! To avoid missing promotions in the future, consider subscribing to dotTech: RSS Feed [2] | E-mail [3] | Twitter [4] | Facebook [5].
dotTech is once again doing its thing and bringing you freebies [6]. This time it is a program by the name of mediAvatar DVD Converter, from mediAvatar Co., Ltd. – a name I am sure most dotTechies are familiar with seeing as dotTech has reviewed a couple of their products recently.
mediAvatar DVD Converter is, as the name implies, a program that allows users to rip/backup DVDs to different video formats, including formats specifically configured to work on electronic devices such as the iPhone, iPad, Xbox, etc. The following is a description of mediAvatar DVD Converter, as per the developer:
The following are all the input/output formats and electronic devices supported by mediAvatar DVD Converter, as per the developer:
Although it is not explicitly stated on the product page or product description, I talked to a mediAvatar Co, Ltd. representative and I was told mediAvatar DVD Converter does bypass DRM protection.
That said, for the next 72-hours (starting 00:00 PST December 15, 2010 and ending 24:00 PST December 17, 2010) everyone can mediAvatar DVD Converter for free! Also part of this 72-hour promotion, dotTechies can get mediAvatar Multimedia Suite at the discounted price of $69.99 [7]. mediAvatar Multimedia Suite [8] is an all-in-one suite that includes a DVD converter, video converter, and audio converter.
To get mediAvatar DVD Converter for free, follow these simple directions:
Version being given out for free: v6.0.12 Build 0919
Free updates: Yes, but minor updates only (i.e 6.x updates only)
Free technical support: Yes, but for one month only
Supported OS: Windows XP SP2+/Vista/Win7
Download size: 28.5 MB
Giveaway time-frame: This giveaway starts on 00:00 PST December 15, 2010 and ends 24:00 PST December 17, 2010. You are allowed to install/reinstall the program after this 72-hour time-frame but if you lose the registration key, you will not be provided with another one.
Note: Unless specifically stated otherwise in this article, mediAvatar DVD Converter has not been tested or reviewed by dotTech (aside from ensuring that this giveaway is valid). All the information about the program in this post is based off the information provided on the developer's website. Please do not take this post as an endorsement/rejection or review of the program. This article is simply to inform about the availability of this program as a freebie; nothing more, nothing less.
Note: This promotion is available to everyone – everyone may get it for free. However, this is a dotTech.org promotion. Please do not directly link to, copy, paste, share, or reprint the promotion page URL or the registration code anywhere else including private or public forums, blogs, file hosting services, etc. If you want to spread information about this offer, you may link to this article by providing a permalink [10] (alternative permalink [11]) to your audience. If you respect our wishes, we will be able to continue to bring you great freebies. If you don't, we have no incentive to continue our promotions and they may stop.
If you have trouble getting mediAvatar DVD Converter for free, post below and other dotTechies or I will try to help.
Please only use mediAvatar DVD Converter for legal purposes, as defined by the laws of your country/region. dotTech, Ashraf, or anyone else except yourself is not responsible for any illegal activity conducted with mediAvatar DVD Converter.
Article printed from dotTech: http://dottech.org
URL to article: http://dottech.org/19630/dottech-promo-free-mediavatar-dvd-converter-72-hours-only/
URLs in this post:
[1] Image: http://dottech.org/wp-content/uploads/2010/12/2010-12-14_222811.png
[2] RSS Feed: http://dottech.org/feed
[3] E-mail: http://dottech.org/e-mail-reminders
[4] Twitter: http://twitter.com/dotTechdotorg
[5] Facebook: http://www.facebook.com/pages/dotTech/112147582153918
[6] bringing you freebies: http://dottech.org/category/freebies/dottech-promo
[7] discounted price of $69.99: http://www.mediavideoconverter.com/webapp/pay.php?product_code=mvc-dottech-special
[8] mediAvatar Multimedia Suite: http://www.mediavideoconverter.com/multimedia-suite.html
[9] promotion page: http://dottech.org/go/mediavatardvdconverterpromotionpage/
[10] permalink: http://dottech.org/freebies/19630
[11] alternative permalink: http://muftapps.com/freebies/19630
[12] Image: http://dottech.org/wp-content/uploads/2010/12/2010-12-14_230251.png
[13] Download: http://www.mediavideoconverter.com/webapp/downloader.php?product_code=mvc-dvd-converter6
[14] Image: http://dottech.org/wp-content/uploads/2010/12/2010-12-14_2216192.png
[15] Image: http://dottech.org/wp-content/uploads/2010/12/2010-12-14_2227302.png
Click here to print.
© 2008-2012 dotTech.org | All content is the property of its rightful owner.


text:
Question ? what is the chat line number for Alabama, AL, Montgomery
Are you looking to find the number 1 place to chat with a large amount of single people speaking on the cell phone as there are NOW 247673 ACTIVE callers near Alabama, AL, Montgomery, try our chatline for a 30 mins free trial period Chatline121 Tel: 763-243-9992 is offering a 24/7 phone chat service for singles living in Alabama, AL, Montgomery who are now talking free right now chatting with local brand new callers in your location.
Nobody should be single so please Try free of charge today at Tel: US: 763-243-9992 Once you're certain Chatline121.com is the foremost singles telephone community around you will use this service daily.


text:
15 Adults-Only Indulgent Desserts
Some weeks, neither a dessert nor a cocktail alone can beat the stress. Teamed up in these boozy desserts, however, they're a one-two punch that will drive the worries back to work hours.
Add these restaurants and shops to your GPS for some standout boozy desserts, no baking or cooking required.


text:
This site uses cookies and similar technologies to customize and enhance your online experience. By using this site, you accept our use of these technologies. To learn more, please read our cookie policy.
Raptors Day: Dwane Casey - May 12, 2014
Dwane Casey speaks with the media regarding Raptors Day and what it means for the city of Toronto.


text:
Posted 3:54 PM 4/5/2012 : Rash of car burglaries puts neighborhood on alert
PORT ALLEN - A West Baton Rouge neighborhood is on alert after burglars went through more than a dozen vehicles in their neighborhood, even stealing one.
Nearly 20 vehicles were hit overnight on Emily Drive. Most were just rummaged through, but Andrew Law's truck was stolen.
... Read More


text:
We need to be informed. In this age of IT revolution; after the nazism, communism, socialism, capitalism and more isms, propaganda is being used to try to turn the lie into the truth.
Using well new media, and without giving up our own talents, as suggests military and Freemasons, we can overcome to which closely united, they are lying for their unconditional love, to the money.
Already discovered how to remove the oil spills, of pipelines, and tankers: OCEANOGENIC POWER.
Over the five years to build the first plant and HTS lines to the U.S., we use the last drops of cheap oil, and cleaner, that remain. At 5 years, we eliminate the 20 million barrels per day used by USA. Would reduce by half the addiction of our civilization.
And then we plan to include, the rest of the world.
U.S., EU, or China, have the money, Panama has the final solution. Who will have the courage? Just me?.